PD-1/PD-L1 inhibitor C1|CAS 1675201-83-8|BMS-1

Cas No.:	1675201-83-8
Chemical Name:	(2S)-1-[[2,6-Dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-2-piperidinecarboxylic acid
Synonyms:	PD1/PDL1 inhibitor 1,PD 1/PD L1 inhibitor 1;BMS-1,BMS1,BMS 1
SMILES:	CC1=C(C=CC=C1COC2=CC(=C(C(=C2)OC)CN3CCCC[C@H]3C(=O)O)OC)C4=CC=CC=C4
Formula:	C₂₉H₃₃NO₅
M.Wt:	475.58
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:	[1]. Zhao Y, et al. Depression Promotes Hepatocellular Carcinoma Progression through a Glucocorticoids Mediated Up-Regulation of PD-1 Expression in Tumor infiltrating NK Cells. Carcinogenesis. 2019 Feb 4. [2]. Li K, et al. Development of small-molecule i

Description:

PD-1/PD-L1 inhibitor C1 is a potent and selective small molecule inhibitor of the PD-1/PD-L1 protein/protein interactions with IC50 < 100 nM (PD-1/PD-L1 Homogenous Time-Resolved Fluorescence (HTRF) binding assay). It may potentially be useful in the treatment of cancer as well as infectious diseases such as hepatitis C. The programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction plays a dominant role in the suppression of T cell responses, especially in a tumor microenvironment, protecting tumor cells from lysis,a useful compound immunomodulator compound.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC8381	PD-1/PD-L1 inhibitor 2(BMS-202)	PD-1/PD-L1 inhibitor 2 is reported to prevent the interaction of PD-L1 with PD-1 with an IC50 value of 18 nM,a useful compound immunomodulator compound.
DC9280	BMS-1 (PD1/PDL1 inhibitor 1)	PD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor,IC50 values: 0.006-0.10 μM,a useful immunomodulator compound.
DC10330	PD-1-IN-17	PD-1-IN-17 has CAS#CAS:1673560-66-1, which is a programmed cell death-1 (PD-1) inhibitor. PD-1-IN-17 was first reported in patent WO2015033301A1, (Compound 4), inhibits 92% splenocyte proliferation at 100 nM. PD-1-IN-17 may be related to CA-170 (AUPM170), which is a potent PD-1 inhibitor and curreently under clinical trials.

BMS-1 (PD1/PDL1 inhibitor 1)